ChristopherJHoimesDO

Oncology • Durham, NC

Genitourinary Oncology

Associate Professor of Medicine-Bladder/Renal and GU Oncology at Duke University

Join to view full profile

Dr. Hoimes is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Hoimes' full profile

Already have an account?

Office
20 Duke Medicine Cir
Durham, NC 27710
Is this information wrong?

Education & Training

Yale School of MedicineBiomedical Engineering , 2008 - 2012
Yale-New Haven HospitalFellowship, Genitourinary Oncology, 2009 - 2010
Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
Penn State Milton S Hershey Medical CenterChief Residency, Internal Medicine, 2005 - 2006
Penn State Milton S Hershey Medical CenterResidency, Internal Medicine, 2002 - 2005
NYIT College Of Osteopathic MedicineClass of 2001

Certifications & Licensure

NC State License 2020 - 2024
OH State License 2013 - 2024
CT State License 2009 - 2013
PA State License 2002 - 2012

Clinical Trials

Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer Start of enrollment: 2013 Apr 01
Completed
Phase 2
Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects Start of enrollment: 2015 May 27
Active, not recruiting
Phase 1, Phase 2

Publications & Presentations

PubMed

2 citations
Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pem...
Milowsky, M., O'Donnell, P., Hoimes, C., Petrylak, D., Flaig, T., Moon, H., Friedlander, T., Mar, N., McKay, R., Srinivas, S., Gravis, G., Ramamurthy, C., Bupathi, M.,...> ;Journal of Clinical Oncology. 2024 Jan 12
Intratumoural immunotherapy plus focal thermal ablation for localized prostate cancer.
Séguier, D., D'Anniballe, V., Michael, Z., Deivasigamani, S., Olivier, J., Villers, A., Adams, E., Kotamarti, S., Hoimes, C., Polascik, T.> ;Nature Reviews. Urology. 2023 Dec 19
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma.
Msaouel, P., Sweis, R., Bupathi, M., Heath, E., Goodman, O., Hoimes, C., Milowsky, M., Davis, N., Kalebasty, A., Picus, J., Shaffer, D., Mao, S., Adra, N., Yorio, J., ...> ;European Urology Oncology. 2023 Dec 16
A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumab.
Christopher J Hoimes, Thomas W Flaig, Matthew I Milowsky, Terence W Friedlander, Mehmet Asim Bilen, Shilpa Gupta, Sandy Srinivas, Jaime R Merchan, Rana R McKay, Daniel...> ;Future Oncology. 2024 Mar 1
Assessing the utility of molecular diagnostic classification for cancers of unknown primary.
Elle C Moore, Gerard C Blobe, Nicholas C DeVito, Brent A Hanks, Michael R Harrison, Christopher J Hoimes, Jingquan Jia, Michael A Morse, Parvathy Jayaprakasan, Andrew ...> ;Cancer Medicine. 2023 Oct 1
16 citations
Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer.
Peter H O'Donnell, Matthew I Milowsky, Daniel P Petrylak, Christopher J Hoimes, Thomas W Flaig, Nataliya Mar, Helen H Moon, Terence W Friedlander, Rana R McKay, Mehmet...> ;Journal of Clinical Oncology. 2023 Sep 1
Outcomes of Antineoplastic Immunotherapy at a Large Healthcare Organization: Impact of Provider, Race and Socioeconomic Status.
Matthew M Mirsky, Carley Mitchell, Augustine Hong, Shufen Cao, Pingfu Fu, Seunghee Margevicius, Sulin Wu, Afshin Dowlati, Ariel Nelson, J Eva Selfridge, Nikhil Ramaiya...> ;Cancer Management and Research. 2023 Jan 1
4 citations
Minding the Bathwater: Fertility and Reproductive Toxicity in the Age of Immuno-Oncology.
Anne E Kim, Ariel Nelson, Kyle Stimpert, Rebecca L Flyckt, Nannan Thirumavalavan, Karen C Baker, Sophia C Weinmann, Christopher J Hoimes> ;JCO Oncology Practice. 2022 Dec 1
66 citations
Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer.
Christopher J Hoimes, Thomas W Flaig, Matthew I Milowsky, Terence W Friedlander, Mehmet Asim Bilen, Shilpa Gupta, Sandy Srinivas, Jaime R Merchan, Rana R McKay, Daniel...> ;Journal of Clinical Oncology. 2023 Jan 1
6 citations
Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma.
Rafee Talukder, Dimitrios Makrakis, Genevieve Ihsiu Lin, Leonidas N Diamantopoulos, Scott Dawsey, Shilpa Gupta, Lucia Carril-Ajuria, Daniel Castellano, Ivan de Kouchko...> ;Clinical Genitourinary Cancer. 2022 Dec 1
8 citations
Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma.
Dimitrios Makrakis, Rafee Talukder, Genevieve Ihsiu Lin, Leonidas N Diamantopoulos, Scott Dawsey, Shilpa Gupta, Lucia Carril-Ajuria, Daniel Castellano, Ivan de Kouchko...> ;Clinical Genitourinary Cancer. 2022 Oct 1
3 citations
Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin.
Rafee Talukder, Dimitrios Makrakis, Leonidas N Diamantopoulos, Lucia Carril-Ajuria, Daniel Castellano, Ivan De Kouchkovsky, Vadim S Koshkin, Joseph J Park, Ajjai Alva,...> ;Clinical Genitourinary Cancer. 2022 Apr 1
23 citations
Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study.
Vadim S Koshkin, Nicholas Henderson, Marihella James, Divya Natesan, Dory Freeman, Amanda Nizam, Christopher T Su, Ali Raza Khaki, Chelsea K Osterman, Michael J Glover...> ;Cancer. 2022 Mar 15
64 citations
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort ...
, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , > ;JAMA Oncology. 2021 Nov 4
3 citations
Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer.
Dimitrios Makrakis, Rafee Talukder, Leonidas Nikolaos Diamantopoulos, Lucia Carril-Ajuria, Daniel Castellano, Ivan de Kouchkovsky, Vadim S. Koshkin, Joseph J. Park, Aj...> ;BJU International. 2021 Oct 25
3 citations
High-dose interleukin-2 therapy related adverse events and implications on imaging.
Neal R. Shah, Kianoush Ansari-Gilani, Mohammad S Alhomoud, Christopher J. Hoimes, Nikhil H. Ramaiya, Ezgi Guler> ;Diagnostic and Interventional Radiology. 2021 Sep 1
20 citations
Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma: A Phase 2 Randomized Clinical Trial.
Sumanta K. Pal, Paul Frankel, Amir Mortazavi, Matthew I. Milowsky, Ulka N. Vaishampayan, Mamta Parikh, Yung Lyou, Peng Weng, Rahul R. Parikh, Benjamin A. Teply, Robert...> ;JAMA Oncology. 2021 Oct 1
18 citations
Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes
Park, J., , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , > ;BJU International. 2021 Aug 1
16 citations
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer.
Matthew D. Galsky, Arjun Vasant Balar, Peter C. Black, Matthew T. Campbell, Gail S Dykstra, Petros Grivas, Shilpa Gupta, Christoper J Hoimes, Lidia P Lopez, Joshua J. ...> ;Journal for Immunotherapy of Cancer. 2021 Jul 1
20 citations
Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303.
Matthew D. Galsky, Christopher J. Hoimes, Andrea Necchi, Neal D. Shore, J. Alfred Witjes, Gary D. Steinberg, Jens Bedke, Hiroyuki Nishiyama, Xiao Fang, Ritesh S. Katar...> ;Future Oncology. 2021 May 19
25 citations
Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance)
Jonathan E. Rosenberg, Karla A Ballman, Susan Halabi, Pamela J. Atherton, Amir Mortazavi, Christopher Sweeney, Walter M. Stadler, Benjamin A. Teply, Joel Picus, Scott ...> ;Journal of Clinical Oncology. 2021 May 14
15 citations
Small Molecule-Based Prodrug Targeting Prostate Specific Membrane Antigen for the Treatment of Prostate Cancer.
Xinning Wang, Aditi Ashish Shirke, Ethan Walker, Rongcan Sun, Gopolakrishnan Ramamurthy, Jing Wang, Lingpeng Shan, Joey Dacula Mangadlao, Zhipeng Dong, Jing Li, Ziying...> ;Cancers. 2021 Jan 22
32 citations
A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors.
Ali Raza Khaki, Ang Li, Leonidas Nikolaos Diamantopoulos, Natalie J. Miller, Lucia Carril-Ajuria, Daniel Castellano, Ivan de Kouchkovsky, Vadim S. Koshkin, Joseph J. P...> ;European Urology Oncology. 2021 Jun 1
6 citations
Findings on Chest CT Performed in the Emergency Department in Patients Receiving Immune Checkpoint Inhibitor Therapy: Single-Institution 8-Year Experience in 136 Patie...
Daniel A. Smith, Ethan Radzinsky, Sree Harasha Tirumani, Ezgi Guler, Andrew M. Petraszko, Elias Kikano, Christopher J. Hoimes, Nikhil H. Ramaiya> ;AJR. American Journal of Roentgenology. 2021 Sep 1
69 citations
Novel therapies are changing treatment paradigms in metastatic prostate cancer
Eric Powers, Georgia-Sofia Karachaliou, Chester Kao, Michael R. Harrison, Christopher J. Hoimes, Daniel J. George, Andrew J. Armstrong, Tian Zhang> ;Journal of Hematology & Oncology. 2020 Oct 28
Join now to see all

Books/Book Chapters

Cancer: Principles and Practice of Oncology
Chapter: Antimicrotuble Agents
Christopher J Hoimes and L. HarrisEditors: DeVita, Hellman, Rosenberg.Edition 10th,2015
Essentials and Updates in Urologic Oncology
Chapter: Systemic Therapy for Advanced Prostate Cancer
Christopher J Hoimes, G. Gibney, W.M. KellyEditors: Philippe E. Spiess.2013

Lectures

EV-103: Enfortumab vedotin plus pembrolizumab and/or chemotherapy for locally advanced or metastatic urothelial cancer.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Seattle Genetics and Astellas Announce Results from Phase 1 Trial of Investigational Agent Enfortumab Vedotin in Combination with Immune Therapy Pembrolizumab as First-Line Treatment for Advanced Bladder CancerSeptember 28th, 2019